Montes Archimedes Acquisition (ROIV)
(Real Time Quote from BATS)
$11.66 USD
+0.03 (0.26%)
Updated Aug 6, 2025 03:45 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ROIV 11.66 +0.03(0.26%)
Will ROIV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
Other News for ROIV
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide ...
Roivant Sciences (ROIV) Anticipated to Benefit from Brepocitinib Developments | ROIV Stock News
Roivant Sciences placed on 'Positive Catalyst Watch' at JPMorgan
What Does the Market Think About Roivant Sciences?
See How Roivant Sciences Ranks Among Analysts' Top Picks With Strong Buyback Activity